10-K: Entera Bio Faces Going Concern Doubt Amid Rising Losses

Entera Bio Ltd. reported increased net losses and declining revenue in 2025, raising substantial doubt about its ability to continue as a going concern without significant additional funding.

Summary

• Entera Bio Ltd. is a clinical-stage company developing first-in-class oral tablet formats of peptides or protein replacement therapies, leveraging its N-Tab platform.
• The company reported a net loss of $11.4 million in 2025, an increase from $9.5 million in 2024.
• Operating loss for 2025 was $11.5 million, up from $9.6 million in 2024.
• Revenue significantly decreased to $42 thousand in 2025 from $181 thousand in 2024, primarily from research services.
• As of December 31, 2025, the accumulated deficit reached $125.4 million.
• Management believes existing cash and cash equivalents of $14.9 million (including $7.8 million restricted for collaboration) will fund operations through the middle of the third quarter of 2026, *excluding* the initiation of the Phase 3 study for EB613.
• Substantial doubt exists about the company's ability to continue as a going concern, as noted by management and the independent registered public accounting firm.
• The lead product candidate, EB613 (oral teriparatide for osteoporosis), has received FDA concurrence for a Phase 3 study with total hip BMD as the primary endpoint, and the FDA qualified total hip BMD as a surrogate efficacy endpoint in December 2025.
• A Phase 3 protocol for EB613 was submitted to the FDA in February 2026, with initiation planned for the second half of 2026, contingent on additional funding.
• EB612 (oral LA-PTH for hypoparathyroidism) showed promising preclinical PK/PD data supporting once-daily dosing, leading to an expanded collaboration with OPKO in February 2026 for joint development.
• The oral GLP-1/Glucagon (EB618) program, in collaboration with OPKO, demonstrated significant systemic exposure and favorable PK profile in preclinical models, with an IND filing for the oral formulation planned after OPKO's subcutaneous Phase 1 data (expected end of 2026).
• The oral GLP-2 program for short bowel syndrome showed a prolonged plasma half-life and sustained systemic exposure in mini-pig studies, supporting once-daily oral dosing.
• The company's global patent portfolio includes issued patents and applications for its N-Tab platform and product candidates, with some composition-of-matter patents in-licensed from OPKO expiring in 2045-2046.
• The Israel-Hamas conflict and regional instability have not materially impacted business or operations to date, but geopolitical risks could affect capital raising.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a low sentiment score due to significant and increasing financial losses, a substantial accumulated deficit, and explicit 'going concern' doubt. While there is positive clinical and regulatory progress, the immediate and substantial need for additional capital for key programs presents a critical financial challenge.

Positives

• FDA provided concurrence for a 2-year, placebo-controlled Phase 3 study for EB613 in osteoporosis, using total hip BMD as the primary endpoint, a significant regulatory milestone.
• The FDA officially qualified total hip BMD as a validated surrogate efficacy endpoint for fracture in new anti-osteoporosis therapies in December 2025, potentially streamlining future drug development.
• Preclinical findings for EB612's proprietary long-acting PTH (LA-PTH) analog demonstrated a markedly prolonged plasma half-life and sustained elevation of serum calcium levels for over three days, supporting once-daily oral dosing for hypoparathyroidism.
• The collaboration with OPKO for the LA-PTH hypoparathyroidism program was expanded in February 2026, with development costs shared equally and an IND application expected in late 2026.
• Oral OXM (EB618) showed significant systemic exposure and a favorable pharmacokinetic profile in preclinical models, with plasma concentrations comparable to the approved oral GLP-1 analog, semaglutide (Rybelsus).
• Preclinical data for the oral GLP-2 analog demonstrated a plasma half-life approximately 18 times longer than teduglutide in mini-pigs, supporting once-daily oral dosing for short bowel syndrome.
• Entera retains global rights to its most advanced product candidate, EB613, offering full commercialization potential if approved.

Negatives

• Net loss increased to $11.4 million in 2025 from $9.5 million in 2024, indicating worsening financial performance.
• Operating loss increased to $11.5 million in 2025 from $9.6 million in 2024.
• Revenue declined significantly to $42 thousand in 2025 from $181 thousand in 2024.
• The company has an accumulated deficit of $125.4 million as of December 31, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern, as stated by management and the independent auditors.
• Existing cash resources are only sufficient to fund ongoing operations through the middle of the third quarter of 2026, *excluding* the initiation of the Phase 3 study for EB613, highlighting an immediate and significant funding gap.
• The company has a limited operating history and no history of late-stage clinical studies or commercializing pharmaceutical products, making future viability uncertain.

Risks

• The company has incurred significant losses since inception and anticipates continued substantial losses for several years.
• All product candidates are in preclinical or clinical phases, with no successful completion of development for any candidate yet.
• Serious adverse side effects identified during development or after approval could delay/halt trials, limit labels, or lead to product liability claims.
• Clinical trials can be delayed or prevented due to difficulties in patient enrollment, regulatory approvals, or third-party contractor performance.
• Results from previous clinical trials may not be predictive of future results, and trials may not be designed to support regulatory approval.
• Ongoing government regulation and potential failure to comply with current and future laws could delay or prevent product promotion, marketing, or sale.
• Healthcare legislative changes, including cost-containment measures and pricing reforms, may harm business and future prospects.
• Manufacturing risks, including lack of commercial-scale experience, complexity of large molecule manufacturing, and compliance with cGMP regulations, could increase costs and limit supply.
• High dependence on raising additional capital or securing strategic partnerships, which may not be available on acceptable terms or at all, potentially delaying or curtailing product development.
• Failure to establish, maintain, defend, and enforce intellectual property rights could allow competitors to use technologies and erode competitive advantage.
• The price of ordinary shares may be volatile due to clinical trial results, funding needs, competitive landscape, and general market conditions.
• The company's status as a smaller reporting company and non-accelerated filer may make its shares less attractive to investors and hinder capital raising.
• Potential delisting from Nasdaq Capital Market if compliance with listing standards (e.g., minimum bid price) is not maintained.
• Dependence on information technology systems, infrastructure, and data, with risks of failures or security breaches leading to disruption or data loss.
• Risks related to employee misconduct, including noncompliance with regulatory standards and insider trading.
• Exposure to costly and damaging product liability claims, potentially exceeding insurance coverage.
• Restrictive data privacy regulations (HIPAA, GDPR, CCPA) impose significant compliance costs and risks of penalties for non-compliance.
• Global economic conditions, including inflation, interest rate hikes, and geopolitical tensions (e.g., Israel-Hamas conflict), may negatively affect operations and magnify risks.
• Israeli government grants impose restrictions on manufacturing and technology transfer outside Israel, with potential penalties up to 600% of the grant amount plus interest.
• Security, political, and economic instability in the Middle East, particularly the Israel-Hamas conflict and broader regional tensions, could harm business operations and capital raising efforts.

Future Outlook

The company plans to initiate the Phase 3 study for EB613 in osteoporosis in the second half of 2026, subject to regulatory feedback and securing additional funding. An IND application for the LA-PTH hypoparathyroidism program is expected to be submitted to the FDA in late 2026. An IND for the oral OXM tablet formulation is planned after OPKO initiates and provides data from its subcutaneous Phase 1 clinical study (expected by end of 2026). The company expects to continue incurring significant expenses and losses for the foreseeable future as it advances its clinical candidates and invests in preclinical programs.

Management Comments

• Management is of the opinion that its available funds as of December 31, 2025, will be sufficient to support ongoing operations under current plans through the middle of the third quarter of 2026, *excluding* the initiation of the Phase 3 study for EB613 in osteoporosis.
• Management continually evaluates various financing alternatives and strategic collaborations, as the Company will need to finance future research and clinical development with additional capital.

Industry Context

StockSavvy.ai notes that Entera Bio operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically targeting chronic conditions with oral peptide therapies. The company's N-Tab platform aims to address the significant treatment gap created by cumbersome injectable protein therapies. The FDA's qualification of total hip BMD as a surrogate endpoint for osteoporosis is a positive industry-wide development that could accelerate drug approvals, potentially benefiting Entera Bio's EB613. The collaborations with OPKO for GLP-1/Glucagon and LA-PTH programs position Entera Bio in high-value therapeutic areas like obesity and hypoparathyroidism, where there is strong market demand for improved delivery methods. However, the industry faces increasing scrutiny over drug pricing and reimbursement, which could impact future commercial success.

Comparison to Industry Standards

• EB613's Phase 2 results showed comparable total hip BMD increases to Forteo (teriparatide SC injection, Eli Lilly) at 6 months, a well-established anabolic drug on the market for over 20 years.
• The oral OXM program's high plasma concentrations and prolonged systemic exposure in preclinical models were consistent with the reported half-life for semaglutide (Rybelsus), the only approved oral GLP-1 analog, suggesting competitive pharmacokinetic potential.
• The oral GLP-2 analog's plasma half-life of approximately 15 hours in mini-pigs is significantly longer than teduglutide (Gattex), which has a half-life of only 0.85 hours in the same species, indicating a potentially superior dosing profile for short bowel syndrome.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Related Party Transactions

• Collaboration and license agreements with OPKO Health, Inc. and its subsidiary OPKO Biologics Ltd. for EB612 (LA-PTH) and EB618 (Oral GLP-1/Glucagon) programs, involving shared development costs and proceeds.
• Issuance and sale of 3,685,226 ordinary shares to OPKO for $8.0 million, with proceeds restricted for development cost obligations under the collaboration agreement.
• Patent Transfer Agreement with Oramed Ltd. (now Oramed NewCo Inc.) obligating the company to pay 3% royalties on net revenues from assigned patent rights.
• Indemnification agreements with directors and officers, covering losses and expenses from their service to the company.

Stakeholder Impact

• Shareholders face significant risk due to recurring losses, substantial doubt about the company's ability to continue as a going concern, and the need for additional dilutive financing.
• Employees may experience uncertainty regarding job security given the company's financial position and dependence on future funding.
• Potential for new treatment options for patients with osteoporosis, hypoparathyroidism, obesity, metabolic disorders, and short bowel syndrome if product candidates are successfully developed and commercialized.
• Collaborators like OPKO are actively involved in co-development and funding, indicating continued partnership, but also shared risks and rewards.
• Creditors face increased risk due to the company's accumulated deficit and going concern warning.

Next Steps

• Initiate the Phase 3 study for EB613 in osteoporosis in the second half of 2026, subject to regulatory feedback and securing additional funding.
• Submit an IND application to the FDA for the LA-PTH hypoparathyroidism program in late 2026.
• File an IND for the oral OXM tablet formulation after OPKO initiates and provides data from its subcutaneous Phase 1 clinical study (expected by end of 2026).
• Continue to evaluate market conditions, liquidity profile, and financing alternatives, including out-licensing arrangements, to enhance capital structure.

Key Dates

Recommendation

The filing reveals a critical financial situation with substantial doubt about the company's ability to continue as a going concern, driven by increasing net losses and declining revenue. While there is positive clinical and regulatory progress for its pipeline, the immediate and significant need for additional capital to fund the lead Phase 3 program, coupled with the inherent risks of drug development and market competition, presents an extremely high-risk investment profile. A seasoned investor would prioritize financial stability, which is severely lacking here, making the stock a strong sell despite any scientific promise.

Keywords

Oral Peptides, N-Tab Platform, Osteoporosis, Hypoparathyroidism, GLP-1/Glucagon, Short Bowel Syndrome, EB613, EB612, EB618, OPKO, Clinical Stage, Biotechnology, SEC Filing, 10-K, Going Concern, Drug Development, Regulatory Approval, Bone Mineral Density, Teriparatide, PTH(1-34), Oxyntomodulin, GLP-2, Israel